Clinical trial · Observational

A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022

NCT07317713CI-TRIAL-00100075completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Carcinoid Tumor	Neuroendocrine Tumor	ALIAS	0.90

Interventions

Interventions (0)

Data not yet available

No intervention recorded.

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
The standardized mortality ratio of GI carcinoid tumors
timeFrame
2000-2022
description
SEER\*Stat software (version 9.0.42.0) was used to conduct data extraction and statistical analysis. The MP-SIR session was used to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death to other non-cancer causes of death across different time intervals and primary sites among GI carcinoid tumour.

Eligibility

Eligibility (as posted)

Sex: All

Show eligibility criteria text

Inclusion Criteria:

* patients diagnosed with gastrointestinal carcinoid tumor
* from 2000-2022
* histologically confirmed

Exclusion Criteria:

* death certificate only and autopsy only patients
* patients with unknown age data.

References

Publications (0)

Data not yet available

No reference posted for this study.